This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Second-line treatment for serious toxicity

Authoring team

Consult expert advice.

If first-line treatment for digoxin toxicity fails, the intervention of choice is Digoxin Specific Fab (DSFab) therapy:

  • DSFab's are biologically active fragments of digoxin- neutralising antibodies
  • patients respond within 30 min, with full effect seen in 3-4 hr
  • the dose of DSFab is calculated by multiplying the amount of digoxin ingested by 60 e.g. 5 mg of digoxin is neutralised by 300 mg of DSFab

Other treatments:

  • propranolol:
    • 1-2 mg i.v. slowly to control ectopics and tacharrythmias

  • atropine:
    • 0.6 mg i.v. may control bradycardias

  • temporary pacing if there is persistent heart block

  • DC cardioversion:
    • risks of inducing heart block or tachycardias
    • indicated in cases of life-threatening arrythmia where DSFab is not considered appropriate
    • cardioversion should begin with low energies e.g. 10 J

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.